Patents Assigned to Praecis Pharmaceuticals, Inc.
-
Publication number: 20060293217Abstract: Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged periods of time, e.g., one month, after administration. Methods for preparing these pharmaceutical compositions, as well as methods of using them to treat a subject are also provided.Type: ApplicationFiled: August 15, 2005Publication date: December 28, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Nicholas Barker, Janet Wolfe
-
Publication number: 20060223758Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: March 24, 2006Publication date: October 5, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Publication number: 20060223866Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.Type: ApplicationFiled: February 6, 2006Publication date: October 5, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Ghotas Evindar, Hongfeng Deng, Barry Morgan
-
Patent number: 7109171Abstract: Methods for treating FSH related conditions, such as prostatic intraepithelial neoplasia, pedophilia, infertility, or vaginal bleeding, with GnRH antagonists are disclosed. The methods of the invention generally feature administering to a subject a GnRH antagonist suitable for in vivo administration and able to reduce both plasma FSH and LH levels in a subject, in an amount or in a formulation effective to reduce plasma FSH levels in the subject to a symptom alleviating level. In vitro fertilization and male contraceptive methods are also provided.Type: GrantFiled: February 28, 2001Date of Patent: September 19, 2006Assignee: Praecis Pharmaceuticals Inc.Inventors: Marc B. Garnick, Paul M. Martha, Jr., Christopher J. Molineaux, Alex DePaoli
-
Patent number: 7105482Abstract: The present invention provides methods of treating, parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.Type: GrantFiled: May 2, 2003Date of Patent: September 12, 2006Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Publication number: 20060198815Abstract: Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged periods of time, e.g., one month, after administration. Methods for preparing these pharmaceutical compositions, as well as methods of using them to treat a subject are also provided.Type: ApplicationFiled: November 2, 2005Publication date: September 7, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Nicholas Barker, Janet Wolfe
-
Publication number: 20060177417Abstract: The present invention provides pharmaceutical formulations comprising a solid ionic complex of a polypeptide having an isoelectric point lower than physiological pH and an anionic carrier molecule. The formulations of the invention are suitable as depot formulations for the sustained release of therapeutic polypeptides.Type: ApplicationFiled: August 15, 2005Publication date: August 10, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Musso, Nicholas Barker, Janet Wolfe, Ming Ye
-
Patent number: 7084108Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: GrantFiled: November 1, 2001Date of Patent: August 1, 2006Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
-
Patent number: 7037890Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: GrantFiled: October 5, 2001Date of Patent: May 2, 2006Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
-
Patent number: 7037889Abstract: Sustained delivery formulations comprising a water-insoluble complex of a peptide and a plurality of ligands are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. Methods of making the complexes of the invention, and methods of these complexes are also disclosed.Type: GrantFiled: September 13, 2001Date of Patent: May 2, 2006Assignee: Praecis Pharmaceuticals Inc.Inventor: Malcolm L. Gefter
-
Publication number: 20060069028Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: September 27, 2005Publication date: March 30, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft
-
Publication number: 20060014696Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.Type: ApplicationFiled: September 30, 2003Publication date: January 19, 2006Applicant: Praecis Pharmaceuticals, Inc.Inventors: Mark Findeis, Malcolm Gefter, Gary Musso, Ethan Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar-Panicucci, Christopher Arico-Muendel, Kathryn Phillips, Neil Hayward
-
Publication number: 20050239878Abstract: The instant invention provides compositions and methods for treating a subject suffering from one of a number of conditions, including an angiogenic disease, such as cancer, an autoimmune disorder or a parasitic infection.Type: ApplicationFiled: December 29, 2004Publication date: October 27, 2005Applicant: Praecis Pharmaceuticals, Inc.Inventors: Charles Thompson, Christopher Arico-Muendel
-
Publication number: 20050233970Abstract: The present invention provides compositions and methods for treating QT prolongation in a subject in need thereof. The method comprises the step of administering to the subject a therapeutically effective amount of an agent which increases the androgen level of the subject.Type: ApplicationFiled: March 23, 2005Publication date: October 20, 2005Applicant: Praecis Pharmaceuticals, Inc.Inventor: Marc Garnick
-
Publication number: 20050158765Abstract: The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag.Type: ApplicationFiled: December 17, 2004Publication date: July 21, 2005Applicant: Praecis Pharmaceuticals, Inc.Inventors: Barry Morgan, Stephen Hale, Christopher Arico-Muendel, Matthew Clark, Richard Wagner, David Israel, Malcolm Gefter, Dennis Benjamin, Nils Hansen, Malcolm Kavarana, Steffen Creaser, George Franklin, Paolo Centrella, Raksha Acharya
-
Patent number: 6919307Abstract: The present invention provides methods of treating a parasitic infection, a lymphoid malignancy or an autoimmune disorder in a subject by administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising a MetAP-2 inhibitory core coupled to a peptide.Type: GrantFiled: May 2, 2002Date of Patent: July 19, 2005Assignee: Praecis Pharmaceuticals, Inc.Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
-
Publication number: 20050137128Abstract: Compounds that modulate natural ? amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a ? amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a ? amyloid peptide, preferably a retro-inverso isomer of A?17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group.Type: ApplicationFiled: November 15, 2004Publication date: June 23, 2005Applicant: Praecis Pharmaceuticals, Inc.Inventors: Mark Findeis, Kathryn Phillips, Gary Olsen, Christopher Self
-
Publication number: 20050059585Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.Type: ApplicationFiled: May 2, 2003Publication date: March 17, 2005Applicant: Praecis Pharmaceuticals Inc.Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
-
Publication number: 20040110689Abstract: Methods for treating hormone associated conditions, such as endometriosis, uterine leiomata, ovarian cancer, breast cancer, or vaginal bleeding, using LHRH antagonists and selective estrogen receptor modulators are disclosed. The methods include administering to a subject a combination of an LHRH antagonist and a selective estrogen receptor modulator. Pharmaceutical compositions and kits for use in the methods of the invention are also provided.Type: ApplicationFiled: July 14, 2003Publication date: June 10, 2004Applicant: Praecis Pharmaceuticals, Inc.Inventor: Marc B. Garnick
-
Patent number: 6703367Abstract: Methods to inhibit hot flashes or gynaecomastia in a subject are provided. In the methods of the invention, an LHRH antagonist is administered to a subject in need of treatment for hot flashes or gynaecomastia such that hot flashes or gynaecomastia are inhibited in the subject. In a particularly preferred embodiment, the invention provides a method for inhibiting menopause-related hot flashes in which an LHRH antagonist is administered to a subject in need of treatment for menopause-related hot flashes such that the hot flashes are inhibited in the subject.Type: GrantFiled: February 16, 2001Date of Patent: March 9, 2004Assignee: Praecis Pharmaceuticals Inc.Inventor: Marc B. Garnick